Submissions from 2026
Phase II clinical trial of nirogacestat in patients with relapsed ovarian granulosa cell tumours, Paul Celano
Updated outcomes from STAMP: Surgically treated adjuvant Merkel cell carcinoma with pembrolizumab, a phase III trial—ECOG-ACRIN EA6174., Gary I. Cohen
KANDLELIT-014: A phase 2 study of MK-1084 as monotherapy and in combination with cetuximab in KRAS G12C-mutant advanced solid tumors., Nehal Lakhani, Changhoon Yoo, Cornelia Schuster, Iván Victoria, Jeesun Yoon, Joon Oh Park, Paul Celano, Tormod Kyrre Guren, Roman Groisberg, Chie-Schin Shih, Thomas Jemielita, and William Bennion McKean
EA3231: A randomized phase III study of BRAF-targeted therapy vs cabozantinib in RAI-refractory differentiated thyroid cancer with BRAF V600Em., Lova Sun, Barabra Burtness, Yael Flamand, Laila A. Gharzai, Mei Tang, and Nabil F. Saba
Systemic Treatment of Thyroid Cancer: ASCO Guideline, Mei Tang
Submissions from 2025
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update, Paul Celano
Submissions from 2024
Lunchbox trial: A randomized phase III trial of cisplatin and irradiation followed by carboplatin and paclitaxel versus sandwich therapy of carboplatin and paclitaxel followed by irradiation then carboplatin and paclitaxel for advanced endometrial carcinoma, Joyce N. Barlin, Barb Mahar, Asahr Ata, Beatrice Cormier, David Michelin, Ritu Salani, Floor Backes, Kimberly Levison, Leigh Ann Cantrell, Lori Weinberg, Allison Wagreich, Duncan Savage, Christian Gasson, Kyle Denniston, Jovana Martin, Timothy McElrath, and Patrick F. Timmins
Representation of women in clinical trials supporting FDA-approval of contemporary cancer therapies, Beryl Otieno
Submissions from 2023
Letter to the Editor: Re: Reimagining Cancer Staging in the Era of Evolutionary Oncology, Elliot A. Asare, Robert K. Brookland, Jeffrey E. Gershenwald, Heidi Nelson, and Mary Kay Washington
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134, Michael B. Atkins, Sandra J. Lee, Chmielowski Bartosz, Ahmad A. Tarhini, Gary I. Cohen, Trach-Giao Truong, Helen H. Moon, Diwakar Davar, Mark O'Rourke, Joseph J. Stephenson, Brendan D. Curti, Walter J. Urba, Joanna M. Brell, Pauline Funchain, Kari L. Kendra, Alexandra P. Ikeguchi, Anthony Jaslowski, Charles L. Bane, Mark M. Taylor, and Manhuri M. Bajaj
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.3, Ishmael A. Jaiyesimi, Dwight H. Owen, Nofisat Ismaila, Elizabeth Blanchard, Paul Celano, Narjust Florez, Dharamvir Jain, and Navneet Singh
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.3, Ishmael A. Jaiyesimi, Dwight H. Owen, Nofisat Ismaila, Elizabeth Blanchard, Paul Celano, Narjust Florez, Dharamvir Jain, and Navneet Singh
Postmenopausal mixed gestational trophoblastic neoplasia with complete response to immunotherapy - A case report, Benjamin J. Matthews, Allison Froehlich, Lindsay Goicochea, and Kimberly L. Levinson
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.2, Dwight H. Owen, Navneet Singh, Nofisat Ismaila, Elizabeth Blanchard, Paul Celano, Narjust Florez, Dharamvir Jain, Natasha B. Leighl, Hirva Mamdani, Gregory Masters, Pamela R. Moffitt, Jarushka Naidoo, Tanyanika Phillips, Gregory J. Riely, Andrew G. Robinson, Erin Schenk, Bryan J. Schneider, Lecia Sequist, David R. Spigel, and Ishmael A. Jaiyesimi
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2, Dwight H. Owen, Navneet Singh, Nofisat Ismaila, Elizabeth Blanchard, Paul Celano, Narjust Florez, Dharamvir Jain, Natasha B. Leighl, Hirva Mamdani, Gregory Masters, Pamela R. Moffitt, Jarushka Naidoo, Tanyanika Phillips, Gregory J. Riely, Andrew G. Robinson, Erin Schenk, Bryan J. Schneider, David R. Spigel, and Ishmael A. Jaiyesimi
Submissions from 2022
Labile Heme and Heme Oxygenase-1 Maintain Tumor-Permissive Niche for Endometriosis-Associated Ovarian Cancer, Jonathan L. Hecht, Monika Janikova, Reeham Choudhury, Fong Liu, Giacomo Canesin, Lubica Janovicova, Eva Csizmadia, Elisa M. Jorgensen, Katharine M. Esselen, Peter Celec, Kenneth D. Swanson, and Barbara Wegiel
Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609, Laurie E. McLouth, Yue Zheng, Stephanie Smith, F Stephen Hodi, Uma N. Rao, Gary I. Cohen, Thomas T. Amatruda, Shaker R. Dakhill, Brendan D. Curti, Ibrahim Nakhoul, Sreenivasa R. Chandana, Charles L. Bane, David E. Mariner, Sandra J. Lee, Vernon K. Sondak, John M. Kirkwood, Ahmad A. Tarhini, and Lynn I. Wagner
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Navneet Singh, Sarah Temin, Sherman Baker Jr, Elizabeth Blanchard, Julie R. Brahmer, Paul Celano, Narjust Duma, Peter M. Ellis, Ivy B. Elkins, Rami Y. Haddad, Paul J. Hesketh, Dharamvir Jain, David H. Johnson, Natasha B. Leighl, Hirva Mamdani, Gregory Masters, Pamela R. Moffitt, Tanyanika Phillips, Gregory J. Riely, and Andrew G. Robinson
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Navneet Singh, Sarah Temin, Sherman Baker Jr, Elizabeth Blanchard, Julie R. Brahmer, Paul Celano, Narjust Duma, Peter M. Ellis, Ivy B. Elkins, Rami Y. Haddad, Paul J. Hesketh, Dharamvir Jain, David H. Johnson, Natasha B. Leighl, Hirva Mamdani, Gregory Masters, Pamela R. Moffitt, Tanyanika Phillips, Gregory J. Riely, and Andrew G. Robinson
Submissions from 2021
A Translational Approach to Cancer Research, Education and Training, Heather J. Ezelle, Theresa Geiman, Lauren A. Schnaper, Kevin J. Cullen, Rena S. Lapidus, and Bret A. Hassel
Submissions from 2020
Submissions from 2017
Genomic alterations in human epidermal growth factor receptor 2 (HER2/ERBB2) in head and neck squamous cell carcinoma, Christine H. Chung, Alexis Germain, Rathan M. Subramaniam, Andreas M. Heilmann, Kyle Fedorchak, Siraj M. Ali, Vincent A. Miller, Robert A. Palermo, and Carole Fakhry
Summary of the Workshop on the Safe Handling of Hazardous Drugs Cohosted by the National Institute for Occupational Safety and Health and the American Society of Clinical Oncology, Thomas H. Connor, Paul Celano, James N. Frame, and Robin T. Zon
Management of sickle cell disease in patients undergoing cardiac surgery, Todd C. Crawford, Michael V. Carter, Rina K. Patel, Alejandro Suarez-Pierre, Sophie Z. Lin, Jonathan Trent Magruder, Joshua C. Grimm, Duke E. Cameron, William A. Baumgartner, and Kaushik Mandal
Submissions from 2016
Case Report: Collision Tumour of Colon Leiomyosarcoma and Adenocarcinoma, Victoria M. Kim, Lindsay Goicochea, and Sandy H. Fang
Submissions from 2015
Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697), David H. Lawson, Sandra Lee, Fengmin Zhao, Ahmad A. Tarhini, Kim A. Margolin, Marc S. Ernstoff, Michael B. Atkins, Gary I. Cohen, Theresa L. Whiteside, Lisa H. Butterfield, and John M. Kirkwood
Clinical Utility of a Plasma Protein Classifier for Indeterminate Lung Nodules, Anil Vachani, Zane Hammoud, Steven Springmeyer, Neri M. Cohen, Dao Nguyen, Christina Williamson, Sandra Starnes, Stephen Hunsucker, Scott Law, Xiao-Jun Li, Alexander Porter, and Paul Kearney
Submissions from 2014
Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic trioxide, Rebecca F. Carlin
Submissions from 2011
Part 2: implementing clinical trials: a review of the attributes of exemplary clinical trial sites, Robin T. Zon, Gary I. Cohen, Dee Anna Smith, and Allison R. Baer
Submissions from 2010
Basic steps to building a research program, Allison R. Baer, Naftali Baer, Gary I. Cohen, and Susan Devine
Implementing clinical trials: a review of the attributes of exemplary clinical trial sites, Allison R. Baer, Gary I. Cohen, Dee Anna Smith, and Robin Zon
Submissions from 2009
The Ligamp TP53 Assay for Detection of Minimal Residual Disease in Head and Neck Squamous Cell Carcinoma Surgical Margins, Joseph A. Califano and John M. Saunders
Maryland's surgical workforce-2007: an in-depth analysis and implications for the future, Scott E. Maizel
Submissions from 2008
Angiosarcoma complicating systemic sclerosis: a case report, Margaret Fonder and Deborah Douglas
Submissions from 2003
Clinical research by community oncologists, Gary I. Cohen
The Satisfaction with Life Domains Scale for Breast Cancer (SLDS-BC), Gary I. Cohen
Submissions from 2001
Chemotherapy-induced menopause: a literature review, B C. Poniatowski, P Grimm, and G Cohen
Special considerations when treating breast cancer in the elderly, L A. Schnaper and K S. Hughes
Submissions from 1999
Reducing burnout: development of an oncology staff bereavement program, A E. Lewis
Submissions from 1992
Merkel cell carcinoma of the eyelid: a report of two new cases and a review of the literature, H L. Cummings and W R. Green